HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Survival lags for adolescents, young adults with cancer
• Blacks with prostate cancer had poorer survival, less likely to undergo pelvic lymph node dissection than whites
• Dialyzers associated with thrombocytopenia during hemodialysis treatment
• Evidence supports cytology as primary screen for cervical cancer
• FDA approves deferiprone for patients with iron overload
• Further defining the role of parents in the treatment of children with cancer Yoram Unguru, MD, MS, MA
• High blood pressure increased risk of cancer death
• Lag time between HIV, lung cancer diagnosis shrinking
• Model predicts aggressive prostate cancer
• S. gallolyticus-based assays needed in colorectal cancer screening programs
• Study: Aspirin had no effect on stroke, thromboembolism risk in AF patients
• Temozolomide well tolerated, effective in poorly differentiated endocrine carcinoma
• Saving lives on the road to discovery Tanios Bekaii-Saab, MD
• A 76-year-old man with primary breast malignancy, axillary lymphadenopathy Munir Ghesani, MD, FACNM; Irene Dy, MD; Alan Sickles, MD
• ACCENT: Blacks had poorer OS, recurrence-free survival than whites after chemotherapy for colon cancer
• BRCA2 mutation associated with improved survival, chemotherapy response in ovarian cancer
• Fludarabine, alemtuzumab extended PFS by 7 months in CLL
• Occult metastases in NSCLC associated with worse prognosis
• SELECT: Vitamin E associated with increased risk for prostate cancer
• VITAL: No link between acetaminophen, risk for cancer
• Chemotherapy reduced OS in children with low-grade glioma
• More than two-thirds of oncologists lack confidence when dealing with grieving families
• Outcomes of brachytherapy similar to cystectomy in muscle-invasive bladder cancer
• Crizotinib: A novel tyrosine kinase inhibitor Lisa K. Lohr, PharmD, BCPS, BCOP